Lisaca, Reynalyn .

HRN: 28-43-49  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/18/2026
CEFUROXIME 1.5GM (VIAL)
01/18/2026
01/19/2026
IV
1.5g
Q8
S/P NSVD; T/C Endometritis
Pending Pharmacy Acceptance 

 Indication:  Prophylaxis    Type of Infection:  Reproductive Tract    Compliance to guidelines: